Amgen NASDAQ: AMGN p. farmaceutyczny, biotechnologiczny

czyli wszystkie giełdy bardziej rozwinięte niż GPW
slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny

Postautor: slayer74 » 31 maja 2021 12:04

Amgen Rises After Key Lung-Cancer Treatment Cleared by FDA
Amgen's Lumakras treats a specific non-small-cell lung cancer form that scientists had struggled with, calling it 'undruggable.'

Shares of Amgen (AMGN) - Get Report got a boost Friday after the U.S. Food and Drug Administration cleared it to market Lumakras, a drug that treats a non-small cell lung cancer with a specific mutation gene known as KRAS.

"KRAS has challenged cancer researchers for more than 40 years with many deeming it as 'undruggable,'" Amgen Executive Vice President of Research David Reese said in a statement.

"The LUMAKRAS development program was a race against cancer for Amgen's scientists and clinical-trial investigators who together have now successfully delivered this new medicine to patients in less than three years -- from first patient dosed to U.S. regulatory approval."

Amgen shares at last check were up 1.2% at $238.23.

The drug shrank tumors with the KRAS mutation in about 36% of patients in clinical trials. Amgen will list the drug at $17,900 per month in the U.S.

Adverse reactions resulting in permanent discontinuation of the treatment during trial occurred in 9% of patients.

Non-small-cell lung cancer accounts for about 84% of the 2.2 million new lung cancer diagnoses each year, including about 236,000 new cases in the U.S. annually, Amgen said.

Last month, the FDA proposed that the once-daily treatment be compared with a lower daily dose of the drug. Amgen agreed with the suggestion and said that it expected results from that study in late 2022.

Amgen says Lumakras, taken by mouth, is a small-molecule inhibitor that treats patients with KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer.

In March, the company said it was buying Five Prime Therapeutics for $1.9 billion to beef up its cancer-drug pipeline.

https://www.thestreet.com/investing/amg ... red-by-fda
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

REKLAMA


slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny

Postautor: slayer74 » 20 cze 2021 14:20

Undervalued Dividend Growth Stock of the Week: Amgen (AMGN)
by Jason Fieber, Mr. Free at 33 • June 20, 2021

Obrazek

https://dailytradealert.com/2021/06/20/ ... en-amgn-2/

https://www.youtube.com/watch?v=XGK0bx9BoUc
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny

Postautor: slayer74 » 26 cze 2021 23:28

Which is a Better Investment? Amgen vs Bristol-Myers Squibb... the Winner May Surprise You 8)

https://www.youtube.com/watch?v=1ThVdclIbtY
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny

Postautor: slayer74 » 04 sie 2021 15:53

Latest Release
Aug 03, 2021

EPS / Forecast
4.38 / 4.09

Revenue / Forecast
6.53B / 6.46B

Amgen (NASDAQ:AMGN) stock fell 0.8% after the biotech said the pandemic, which has limited patient interactions with healthcare providers, is still expected to hit sales for the rest of 2021.

Amgen (AMGN) reported a 4% EPS
gain as sales rose 5% to $6.53 billion,
but shares fell on trimmed
full-year guidance.
Ostatnio zmieniony 08 sie 2021 21:29 przez slayer74, łącznie zmieniany 1 raz.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny

Postautor: slayer74 » 04 sie 2021 15:58

CVS Health (NYSE:CVS) stock fell 0.9% after the drugstore chain announced its was boosting wages for its employees due to increased competition for labor; the company nonetheless raised its annual earnings forecast.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny

Postautor: slayer74 » 03 lis 2021 11:11

AMGN Earnings
Latest Release
Nov 02, 2021

EPS / Forecast
4.67 / 4.27

Revenue / Forecast
6.71B / 6.67B
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny

Postautor: slayer74 » 17 gru 2021 12:31

Amgen hikes dividend by 10 percent. $AMGN
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny

Postautor: slayer74 » 19 gru 2021 13:01

Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny

Postautor: slayer74 » 07 lut 2022 19:36

Tesla (TSLA) saw a larger reversal and was off 1.3%. The Securities and Exchange Commission subpoenaed Tesla for details on the compliance of settlement requiring a company lawyer to preapprove some of CEO Elon Musk's tweets, Dow Jones reported.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 04 lis 2022 10:17

Amgen Sweetens Full-Year Outlook After Narrowly Beating Third-Quarter Forecasts

ALLISON GATLIN04:53 PM ET 11/03/2022
Amgen stock popped Thursday after the drugmaker sweetened its 2022 outlook following a third-quarter beat that featured strong performances from Evenity and Aimovig.

The drugs treat osteoporosis and migraines, respectively. In the September quarter, sales of both surged 35% year over year. Evenity brought in $201 million with Aimovig trailing at $107 million.

Their growth helped offset a 14% decline for Amgen's biggest moneymaker, inflammation drug Enbrel. Enbrel is facing increasing competition and lower sales prices — a theme Amgen says will continue in the coming years.

Still, Amgen stock jumped less than 1% higher in after-hours trades on today's stock market. Shares were trading near 268.20 after losing 1.2% during the regular session.

Amgen Stock: Profit Grows By Double Digits
Overall, revenue dipped 1% during the quarter to $6.65 billion. Adjusted profit hiked 15% higher to $4.70 per share. Both measures easily beat expectations for $6.56 billion in sales and adjusted earnings of $4.44 a share, according to FactSet.

Enbrel sales tumbled to $1.11 billion. But other big moneymakers put up stout numbers, including Prolia. Sales of the osteoporosis treatment surged 7% to $862 million. Inflammation medicine Otezla brought in $627 million, up 3%.


For the year, Amgen now expects $26 billion to $26.3 billion in sales. Three months ago, the company guided to a midpoint of $25.95 billion in sales this year. Amgen stock analysts called for $26.14 billion in full-year sales.

Amgen also said it expects to earn $17.25 to $17.85 per share for 2022, on an adjusted basis. That's up 55 cents, at the midpoint, from the company's previous guidance. Analysts projected $17.52 in earnings per share.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 01 lut 2023 18:34

Dow component Amgen Inc (NASDAQ:AMGN) slipped 3.7% as the drugmaker said its fourth-quarter revenue fell slightly.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 14 mar 2023 13:33

Amgen & Eli Lilly upgraded to Overweight at Wells Fargo, Merck downgraded to Equal Weight

Wells Fargo upgraded Amgen (NASDAQ:AMGN) and Eli Lilly (NYSE:LLY) while downgrading Merck (NYSE:MRK).

Amgen was upgraded to Overweight from Equal Weight with a price target of $265.00 (from $275.00) as the firm believes the pessimism related to the company post-Horizon Therapeutics (NASDAQ:HZNP) deal has caused weakness, and it now sees the stock trading approximately 7-8% below the worst-case scenario.

“After combining AMGN-HZNP, we see FV of the company at $247 in a no-Tepezza US growth scenario and modest growth in other parts; the stock is trading below this level. Our base case assumes modest US growth and $5B peak sales for HZNP which is much lower than prior HZNP guidance of $6.5B peak,” said the firm.

Shares gained more than 2% today.

Eli Lilly was upgraded to Overweight from Equal Weight with a price target of $375.00 (from $360.00) as recent weakness creates a buying opportunity.

The firm’s previous Equal Weight thesis was based on unfavorable risk/reward for donanemab Alzheimer's data in H1/23 and the stock being priced to perfection for diabetes/obesity franchise.

Wells Fargo believes that the stock, being down 18% (S&P 500 -5%) without fundamental change, presents a good opportunity, given a good R&D engine, absence of near-to-medium-term loss of exclusivity, and that it is not dependent on M&A for growth.

Shares rose 3% today.

Meanwhile, Merck was downgraded to Equal Weight from Overweight with a price target of $115.00 as the firm believes with the recent appreciation of stock, Merck seems fairly valued at ~16x 2023 PE given that it still has Keytruda-related LOE issues to solve.

Shares fell nearly 2% today.

https://www.investing.com/news/stock-ma ... SI-3029469
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 28 kwie 2023 10:10

Latest Release
Apr 27, 2023

EPS / Forecast
3.98 / 3.82

Revenue / Forecast
6.1B / 6.12B

(Reuters) -Amgen Inc on Thursday reported lower first-quarter profit as expenses rose and a 2% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly (NYSE:LLY) and Co.

Amgen (NASDAQ:AMGN) reported revenue of $6.11 billion for the quarter, down 2% from a year earlier, but close to analysts' estimates of $6.17 billion, according to Refinitiv data.

Product sales by volume grew 14% from a year earlier, but net selling prices fell 5%, while foreign exchange rates and other factors also limited sales revenue gains, Amgen said.

Adjusted earnings per share decreased to $3.98 from $4.25 a year ago, but came in ahead of analysts' forecast of $3.85.

Amgen is seeing prescription trends return to prepandemic levels and "demand for medicines is resilient despite current macroeconomic challenges," Amgen Chief Executive Robert Bradway said on a conference call with investors.

Amgen shares, which rose by less than 1% in regular trading, were down 2.3% at $234.83 after hours.

The company said first-quarter sales of cholesterol drug Repatha rose 18% from a year earlier to a record $388 million, while sales of migraine drug Aimovig fell 32%, driven by lower prices.

Sales of psoriasis drug Otezla fell 13% and arthritis drug Enbrel saw sales drop 33%, both due in part to lower net selling prices, Amgen said.

"Misses in core assets like Enbrel fail to provide confidence needed when commercial launches are faltering," BMO Capital Markets analyst Evan Seigerman said in a research note.

Operating expenses for the quarter increased 6%, research and development costs rose 12% and Amgen said its tax rate rose 5.6 percentage points, primarily due to a Puerto Rico tax law change.

The California-based biotechnology company slightly increased its forecast for full-year 2023 revenue to range of $26.2 billion to $27.3 billion, from the previous view of $26 billion to $27.2 billion, excluding the impact of its pending acquisition of Horizon Therapeutics (NASDAQ:HZNP) Plc.

Analysts estimate $26.7 billion in revenue for the full year.

Amgen said it still expects the Horizon deal to close by the end of June.

"The Horizon deal is still a focus to get back to growth and offset headwinds on older products," Jefferies analyst Michael Yee said in a note.

In December, Amgen agreed to buy Horizon for $27.8 billion, fortifying its rare diseases portfolio with the access to blockbuster thyroid eye disease treatment Tepezza.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 18 maja 2023 10:41

FTC stara się zablokować umowę Amgen-Horizon, powołując się na obawy dotyczące monopoli.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Amgen NASDAQ: AMGN p. farmaceutyczny, biotechnologiczny

Postautor: slayer74 » 04 sie 2023 11:59

(Reuters) -Amgen, which is facing U.S. Federal Trade Commission (FTC) delays to its planned acquisition of Horizon Therapeutics (NASDAQ:HZNP), on Thursday reported higher quarterly profit on strong sales of treatments for cholesterol, osteoporosis and other drugs.

The biotech company, which slightly raised its outlook for full-year revenue and profit, said it currently expects the Horizon deal to close by mid-December.

For the second quarter, Amgen (NASDAQ:AMGN) reported revenue of $6.99 billion, up 6% from a year earlier, exceeding analysts' estimates of $6.68 billion, according to Refinitiv data.

Earnings, excluding items, rose 8% to $5.00 per share, ahead of analyst estimates of $4.46 per share.


Product sales by volume grew 11% from a year earlier, but net selling prices fell 2%, while foreign exchange rates and lower inventory levels also limited revenue gains, Amgen said.

"We had nine products with record sales in the quarter," Amgen Chief Financial Officer Peter Griffith said in a phone interview.

Quarterly sales of cholesterol drug Repatha totaled $424 million, beating the average analyst estimate of $372 million, while sales of osteoporosis drug Prolia reached $1.03 billion, compared with the $954 million analysts had forecast.

The results show some "bounce back" after a challenging first quarter that had raised investor fears about a slowdown in Amgen's base business, Jefferies analyst Michael Yee said in a research note.

Sales of Amjevita, Amgen's biosimilar version of AbbVie (NYSE:ABBV)'s blockbuster arthritis drug Humira, totaled $150 million, short of Wall Street expectations of $204 million.

Amgen said U.S. Amjevita sales fell 63% from the first quarter, driven by a drawdown in inventory levels, while sales outside of the U.S. rose 13% from a year earlier.

The California-based company also reported positive results from a mid-stage trial of experimental drug tarlatamab in patients with advanced lung cancer. Amgen said it is discussing with regulators whether the data could be used to seek approval of the drug for patients with relapsed or refractory disease.

For the full year, Amgen modestly raised its outlook for adjusted earnings per share to a range of $17.80 to $18.80 from its prior forecast of $17.40 to $18.60. The company also increased its outlook for 2023 revenue to $26.6 billion to $27.4 billion from $26 billion to $27.2 billion.

Amgen said the forecast does not include any impact from the planned Horizon acquisition.

In a lawsuit, the FTC said it believed Amgen could leverage its big selling drugs to pressure insurance companies and pharmacy benefit managers to favor Horizon's two key products - thyroid eye disease treatment Tepezza and gout drug Krystexxa - over potential competitors.

"We look forward to making our case in court in September," the CFO said.

Amgen shares were up about half a percentage point at $232 after hours.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!


Wróć do „Zagranica”

REKLAMA

Kto jest online

Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 20 gości